Brief Description
Intellia is a leading genome editing company focused on the development of proprietary, potentially curative therapeutics utilizing a recently developed biological tool known as the CRISPR/Cas9 system. Intellia leverages leading scientific expertise, clinical development experience, and intellectual property position to unlock broad therapeutic applications of CRISPR/Cas9 genome editing and develop a potential new drug class.
Timeline
- 2014. Company founded.
Inventors
Jennifer Doudna, Emmanuelle Charpentier, James Doudna Cate, Krzysztof Chylinski, Lei Qi, Martin Jinek, Wendell Lim